Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stock Position in Zoetis Inc. $ZTS

Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 14.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,312,779 shares of the company’s stock after purchasing an additional 550,859 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.98% of Zoetis worth $631,046,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Halbert Hargrove Global Advisors LLC lifted its stake in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares in the last quarter. NewSquare Capital LLC lifted its position in shares of Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares in the last quarter. Financial Consulate Inc. bought a new position in shares of Zoetis in the third quarter worth about $39,000. SJS Investment Consulting Inc. raised its stake in Zoetis by 1,606.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after purchasing an additional 257 shares during the period. Finally, TruNorth Capital Management LLC purchased a new position in Zoetis in the 3rd quarter worth approximately $42,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

NYSE ZTS opened at $129.15 on Thursday. The company has a market cap of $54.52 billion, a P/E ratio of 21.45, a P/E/G ratio of 1.97 and a beta of 0.96. The business’s 50 day moving average price is $125.74 and its 200-day moving average price is $134.31. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.00. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period last year, the company earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Analysts Set New Price Targets

ZTS has been the subject of a number of research analyst reports. JPMorgan Chase & Co. cut their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. HSBC set a $140.00 target price on shares of Zoetis in a research report on Wednesday, December 10th. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, January 28th. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a report on Monday, December 15th. Finally, UBS Group set a $136.00 target price on Zoetis in a report on Thursday, January 29th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.